Stocks in Focus: Marathon Patent Group (NASDAQ:MARA), InfuSystem Holdings (NYSEMKT:INFU), Visa Inc. (NYSE:V), Avalon Holdings Corp. (NYSEMKT:AWX), Merck (NYSE:MRK)

On Friday shares of Marathon Patent Group, Inc. (NASDAQ:MARA) closed at $5.61. Company’s EPS growth for next 5 years is recorded as 50.00%. Marathon Patent Group (NASDAQ:MARA) announced that its wholly-owned subsidiary IP Liquidity Ventures, LLC has entered into a patent purchase agreement pursuant to which it acquired 43 patents related to Tire Pressure Monitoring Systems (TPMS).

InfuSystem Holdings, Inc. (NYSEMKT:INFU) in last trading activity increased 9.59% to close at $3.20. Company weekly performance is 0.95% while its quarterly performance stands at 17.65%. InfuSystem Holdings, Inc. (NYSEMKT:INFU) is -28.89% away from its 52 week high. InfuSystem Holdings, Inc. (NYSEMKT:INFU) announced the Board of Directors has elected Gregg O. Lehman, PhD., as Chairman of the Board of Directors, effective May 13, 2015. Dr. Lehman, a member of the InfuSystem Board since 2014, succeeds Ryan J. Morris, who had served as Chairman since 2012 and will continue to serve on InfuSystem’s Board.

On last trading day Visa Inc. (NYSE:V) decreased -0.61% to close at $69.57. Its volatility for the week is 1.51% while volatility for the month is 2.07%. V’s sales growth for past 5 years was 12.90% and its EPS growth for past 5 years was 25.20%. Visa Inc. (NYSE:V) monthly performance is 6.16%. A consortium of retailers filed a complaint 12 May, accusing Visa Inc. (NYSE:V) and MasterCard Inc of conspiring to fix interchange fees imposed on merchants for the privilege of accepting their credit and debit cards.

Avalon Holdings Corp. (NYSEMKT:AWX) has 0.10% insider ownership while its institutional ownership stands at 29.00%. In last trading activity company’s stock closed at $3.47. Avalon Holdings Corporation (NYSE:AWX) on 14 May, announced financial results for the first quarter of 2015. Net operating revenues in the first quarter of 2015 were $10.7 million compared with $10.0 million in the first quarter of 2014. The Company incurred a net loss of $1.0 million, or $.27 per share in the first quarter of 2014 compared to a net loss of $0.7 million, or $.18 per share in the first quarter of 2014.

Merck & Co. Inc. (NYSE:MRK) has 0.04% insider ownership while its institutional ownership stands at 76.10%. In last trading activity company’s stock closed at $60.23 Merck & Co. Inc. (NYSE:MRK) announced that new investigational data in 10 different types of cancer from the company’s immuno-oncology development program evaluating its anti-PD-1 therapy, KEYTRUDA® , will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology in Chicago, May 29 – June 2, 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *